|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
31,350,000 |
Market
Cap: |
16.03(M) |
Last
Volume: |
15,038 |
Avg
Vol: |
14,997 |
52
Week Range: |
$0.2127 - $0.648 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Catalyst Biosciences is a research and clinical development biopharmaceutical company. Co.'s complement portfolio consists of the development candidates CB 4332 and CB 2782-PEG. CB 4332 is a wholly owned, improved albumin-fused Complement Factor I (CFI) molecule intended for prophylactic subcutaneous or intravitreal administration in individuals with an imbalance in complement homeostasis or a CFI deficiency. CB 2782-PEG is a potential component 3 degrader product candidate in preclinical development for the treatment of dry age-related macular degeneration. Co. has several engineered protease programs in discovery or early non-clinical development.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
9,750 |
Total Buy Value |
$0 |
$0 |
$0 |
$4,584 |
Total People Bought |
0 |
0 |
0 |
3 |
Total Buy Transactions |
0 |
0 |
0 |
3 |
Total Shares Sold |
60,000 |
60,000 |
60,000 |
60,000 |
Total Sell Value |
$950,777 |
$950,777 |
$950,777 |
$950,777 |
Total People Sold |
1 |
1 |
1 |
1 |
Total Sell Transactions |
3 |
3 |
3 |
3 |
End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Toler Steven M. |
VP, Trans Scnces & Emgng OppsO |
|
2012-05-31 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
1,000 |
|
- |
|
Bencherif Merouane |
SVP, Preclinical Research |
|
2012-05-18 |
4 |
OE |
$2.93 |
$46,698 |
D/D |
15,938 |
15,938 |
|
- |
|
Debethizy J Donald |
President and CEO |
|
2012-02-14 |
4 |
OE |
$5.10 |
$4,070 |
D/D |
798 |
798 |
|
- |
|
Caldwell William S |
SVP - Drug Discovery and Dev. |
|
2011-09-20 |
4 |
GA |
$0.00 |
$0 |
I/I |
500 |
500 |
|
- |
|
Caldwell William S |
SVP - Drug Discovery and Dev. |
|
2011-09-20 |
4 |
GD |
$0.00 |
$0 |
D/D |
1,000 |
6,735 |
|
- |
|
Richard John P |
Director |
|
2011-07-01 |
4 |
S |
$21.02 |
$52,550 |
D/D |
(2,500) |
5,333 |
|
- |
|
Richard John P |
Director |
|
2011-07-01 |
4 |
OE |
$9.27 |
$23,175 |
D/D |
2,500 |
7,833 |
|
- |
|
Musso Alan A |
SVP, CFO & Treasurer |
|
2011-06-07 |
4 |
S |
$21.80 |
$672,973 |
D/D |
(30,875) |
2,799 |
|
- |
|
Musso Alan A |
SVP, CFO & Treasurer |
|
2011-06-07 |
4 |
OE |
$5.10 |
$166,340 |
D/D |
30,875 |
33,674 |
|
- |
|
Brown Julia R |
Director |
|
2011-05-13 |
4 |
S |
$23.38 |
$212,782 |
D/D |
(9,100) |
0 |
|
- |
|
Brown Julia R |
Director |
|
2011-05-13 |
4 |
OE |
$8.70 |
$79,170 |
D/D |
9,100 |
9,100 |
|
- |
|
Burrill Steven |
Director |
|
2011-05-12 |
4/A |
S |
$23.88 |
$789,345 |
D/D |
(33,052) |
0 |
|
- |
|
Burrill Steven |
Director |
|
2011-05-12 |
4/A |
OE |
$2.71 |
$241,972 |
D/D |
33,052 |
33,052 |
|
- |
|
Burrill Steven |
Director |
|
2011-05-11 |
4 |
S |
$23.88 |
$789,345 |
D/D |
(33,052) |
0 |
|
- |
|
Burrill Steven |
Director |
|
2011-05-11 |
4 |
OE |
$2.71 |
$241,972 |
D/D |
33,052 |
33,052 |
|
- |
|
Burrill Steven |
Director |
|
2011-05-10 |
4 |
S |
$24.13 |
$48,253 |
I/I |
(2,000) |
0 |
|
- |
|
Burrill Steven |
Director |
|
2011-05-10 |
4 |
S |
$24.04 |
$407,471 |
D/D |
(16,948) |
0 |
|
- |
|
Burrill Steven |
Director |
|
2011-05-10 |
4 |
OE |
$9.37 |
$158,803 |
D/D |
16,948 |
16,948 |
|
- |
|
Richard John P |
Director |
|
2011-04-01 |
4 |
S |
$26.60 |
$66,500 |
D/D |
(2,500) |
5,333 |
|
- |
|
Richard John P |
Director |
|
2011-04-01 |
4 |
OE |
$9.27 |
$23,175 |
D/D |
2,500 |
7,833 |
|
- |
|
Caldwell William S |
SVP - Drug Discovery and Dev. |
|
2011-03-31 |
4 |
S |
$26.37 |
$70,012 |
D/D |
(2,655) |
7,735 |
|
- |
|
Caldwell William S |
SVP - Drug Discovery and Dev. |
|
2011-03-31 |
4 |
OE |
$2.93 |
$7,779 |
D/D |
2,655 |
10,390 |
|
- |
|
Hodges Mauri K |
VP Fin + Corp Sys & Controller |
|
2011-03-07 |
4 |
S |
$30.00 |
$15,001 |
D/D |
(500) |
1,159 |
|
- |
|
Hodges Mauri K |
VP Fin + Corp Sys & Controller |
|
2011-03-07 |
4 |
OE |
$5.55 |
$2,775 |
D/D |
500 |
1,659 |
|
- |
|
Hodges Mauri K |
VP Fin + Corp Sys & Controller |
|
2011-03-03 |
4 |
S |
$30.00 |
$150,900 |
D/D |
(5,030) |
1,159 |
|
- |
|
530 Records found
|
|
Page 8 of 22 |
|
|